awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36546469-A411C29B-0696-4C54-8923-62AC81BB0EC7
Q36546469-A411C29B-0696-4C54-8923-62AC81BB0EC7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36546469-A411C29B-0696-4C54-8923-62AC81BB0EC7
Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.
P2860
Q36546469-A411C29B-0696-4C54-8923-62AC81BB0EC7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36546469-A411C29B-0696-4C54-8923-62AC81BB0EC7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
aeef85c115d7253c08648e348eceacd495973c2d
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer